Energy metabolism and inflammation in brain aging and Alzheimer's disease

Free Radical Biology and Medicine

Volumn 100, Issue , 2016, Pages 108-122

  Yin, Fei ^a   Sancheti, Harsh ^a   Patil, Ishan ^a   Cadenas, Enrique ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Brain aging; Glucose metabolism; Inflammation; Mitochondria; Redox control

Indexed keywords

CRYOPYRIN; SOMATOMEDIN C; HYDROGEN PEROXIDE;

ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; COGNITIVE AGING; ENERGY METABOLISM; GLUCOSE BRAIN LEVEL; GLUCOSE TRANSPORT; HUMAN; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AGING; ANIMAL; BRAIN; INFLAMMATION; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; ENERGY METABOLISM; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION; MITOCHONDRIA; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION;

EID: 84966656933     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.04.200     Document Type: Review

References (246)

1. [1] Imtiaz, B., Tolppanen, A.M., Kivipelto, M., Soininen, H., Future directions in Alzheimer's disease from risk factors to prevention. Biochem. Pharmacol. 88 (2014), 661–670.
2. [2] Rossi, S., Zanier, E.R., Mauri, I., Columbo, A., Stocchetti, N., Brain temperature, body core temperature, and intracranial pressure in acute cerebral damage. J. Neurol. Neurosurg. Psychiatry 71 (2001), 448–454.
3. [3] Blass, J.P., Sheu, R.K., Gibson, G.E., Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. N.Y. Acad. Sci. 903 (2000), 204–221.
4. [4] Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 20:Suppl. 2 (2010), S265–S279.
5. [5] de la Monte, S., Wands, J., Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 7 (2005), 45–61.
6. [6] Harper, S., Economic and social implications of aging societies. Science 346 (2014), 587–591.
7. [7] van Heemst, D., Insulin, IGF-1 and longevity. Aging Dis. 1 (2010), 147–157.
8. [8] Cheng, Z., Tseng, Y., White, M.F., Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21 (2010), 589–598.
9. [9] Swerdlow, R.H., Brain aging, Alzheimer's disease, and mitochondria. Biochim. Biophys. Acta 1812 (2011), 1630–1639.
10. [10] De Felice, F.G., Ferreira, S.T., Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63 (2014), 2262–2272.
11. [11] Spielman, L.J., Little, J.P., Klegeris, A., Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J. Neuroimmunol. 273 (2014), 8–21.
12. [12] Kapetanovic, R., Bokil, N.J., Sweet, M.J., Innate immune perturbations, accumulating DAMPs and inflammasome dysregulation: a ticking time bomb in ageing. Ageing Res. Rev. 24 (2015), 40–53.
13. [13] Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
14. [14] Jiang, T., Cadenas, E., Astrocytic metabolic and inflammatory changes as a function of age. Aging Cell 13 (2014), 1059–1067.
15. [15] Yin, F., Boveris, A., Cadenas, E., Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid. Redox Signal. 20 (2014), 353–371.
16. [16] Yin, F., Sancheti, H., Liu, Z., Cadenas, E., Mitochondrial function in ageing: coordination with signalling and transcriptional pathways. J. Physiol. 594 (2015), 2025–2042.
17. [17] Taneguchi, C.M., Emanuelli, B., Kahn, C.R., Critical nodes in signalling pathways: insights into insulin action. Nature Mol. Cell Biol. 7 (2006), 85–96.
18. [18] Cohen, E., Dillin, A., The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat. Rev. Neurosci. 9 (2008), 759–767.
19. [19] Yin, F., Jiang, T., Cadenas, E., Metabolic triad in brain aging: mitochondria, insulin/IGF-1 signalling, and JNK signalling. Biochem. Soc. Trans. 41 (2013), 101–105.
20. [20] Csiszar, A., Wang, M., Lakatta, E.G., Ungvari, Z., Inflammation and endothelial dysfunction during aging: role of NF-κB. J. Appl. Physiol. 105 (2008), 1333–1341.
21. [21] Lowell, B.B., Shulman, G.I., Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005), 384–387.
22. [22] Havrankova, J., Roth, J., Brownstein, M.J., Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. J. Clin. Invest. 64 (1979), 636–642.
23. [23] van der Heide, L.P., Ramakers, G.M., Smidt, M.P., Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 79 (2006), 205–221.
24. [24] Grillo, C.A., Piroli, G.G., Hendry, R.M., Reagan, L.P., Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 1296 (2009), 35–45.
25. [25] Brüning, J., Gautam, D., Burks, D.J., Gillette, J., Schubert, M., Orban, P.C., Klein, R., Krone, W., Müller-Wieland, D., Kahn, C.R., Role of brain insulin receptor in control of body weight and reproduction. Science 289 (2000), 2122–2125.
26. [26] Kenyon, C., Chang, J., Gensch, E., Rudner, A., Tabtiang, R., A.C. elegans mutant that lives twice as long as wild type. Nature, 366, 1993, 461.
27. [27] Friedman, D.B., Johnson, T.E., A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics 118 (1988), 75–86.
28. [28] Bluher, M., Kahn, B.B., Kahn, C.R., Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299 (2003), 572–574.
29. [29] Taguchi, A., Wartschow, L.M., White, M.F., Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317 (2007), 369–372.
30. [30] BarzilaiL, N., Ferrucci, L., Insulin resistance and aging: a cause or a protective response?. J. Gerontol. A Biol. Sci. Med. Sci. 67 (2012), 1329–1331.
31. [31] Mair, W., Dillin, A., Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem. 77 (2008), 727–754.
32. [32] Jiang, T., Yin, F., Yao, J., Brinton, R.D., Cadenas, E., Lipoic acid restores age-associated impairment of brain energy metabolism through the modulation of Akt/JNK signaling and PGC1a transcriptional pathway. Aging Cell 12 (2013), 1021–1031.
33. [33] Liu, Z., Patil, I.Y., Jiang, T., Sancheti, H., Walsh, J.P., Stiles, B.L., Yin, F., Cadenas, E., High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PLoS One, 10, 2015, e0128274.
34. [34] Sancheti, H., Akopian, G., Yin, F., Brinton, R.D., Walsh, J.P., Cadenas, E., Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. PLoS One, 8, 2013, e69830.
35. [35] Ho, L., Qin, W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C.V., Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004), 902–904.
36. [36] Plaschke, K., Kopitz, J., Siegelin, M., Schliebs, R., Salkovic-Petrisic, M., Riederer, P., Hoyer, S., Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J. Alzheimers Dis. 19 (2009), 691–704.
37. [37] Cao, D., Lu, H., Lewis, T.L., Li, L., Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282 (2007), 36275–36282.
38. [38] Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122 (2012), 1316–1338.
39. [39] Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., Gong, C.-X., Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 225 (2011), 54–62.
40. [40] Kuusisto, J., Koivisto, K., Mykkänen, L., Helkala, E.L., Vanhanen, M., Hänninen, T., Kervinen, K., Kesäniemi, Y.A., Riekkinen, P.J., Laakso, M., Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study. BMJ 315 (1997), 1045–1049.
41. [41] Craft, S., Cholerton, B., Baker, L.D., Insulin and Alzheimer's disease: untangling the web. J. Alzheimers Dis. 33:Suppl. 1 (2013), S263–S275.
42. [42] Teune, L.K., Bartels, A.L., Leenders, K.L., FDG-PET imaging in neurodegenerative brain diseases. Signorelli, F., Chirchiglia, D., (eds.) Functional Brain Mapping and the Endeavor to Understand the Working Brain, 2013, InTech, Rijeka, Croatia.
43. [43] Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., Begdouri, H., Bentourkia, M., Turcotte, E., Allard, M., Barberger-Gateau, P., Fulop, T., Rapoport, S.I., Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27 (2011), 3–20.
44. [44] Mergenthaler, P., Lindauer, U., Dienel, G.A., Meisel, A., Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 36 (2013), 587–597.
45. [45] Craft, S., Insulin resistance syndrome and alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord. 20 (2006), 298–301.
46. [46] Gage, F.H., Kelly, P.A., Bjorklund, A., Regional changes in brain glucose metabolism reflect cognitive impairments in aged rats. J. Neurosci. 4 (1984), 2856–2865.
47. [47] Yin, F., Yao, J., Sancheti, H., Feng, T., Melcangi, R.C., Morgan, T.E., Finch, C.E., Pike, C.J., Mack, W.J., Cadenas, E., Brinton, R.D., The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiol. Aging 36 (2015), 2282–2295.
48. [48] Pardo, J.V., Lee, J.T., Sheikh, S.A., Surerus-Johnson, C., Shah, H., Munch, K.R., Carlis, J.V., Lewis, S.M., Kuskowski, M.A., Dysken, M.W., Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. Neuroimage 35 (2007), 1231–1237.
49. [49] Salat, D.H., Buckner, R.L., Snyder, A.Z., Greve, D.N., Desikan, R.S., Busa, E., Morris, J.C., Dale, A.M., Fischl, B., Thinning of the cerebral cortex in aging. Cereb. Cortex 14 (2004), 721–730.
50. [50] Sowell, E.R., Peterson, B.S., Thompson, P.M., Welcome, S.E., Henkenius, A.L., Toga, A.W., Mapping cortical change across the human life span. Nat. Neurosci. 6 (2003), 309–315.
51. [51] Kochunov, P., Mangin, J.F., Coyle, T., Lancaster, J., Thompson, P., Riviere, D., Cointepas, Y., Régis, J., Schlosser, A., Royall, D.R., Age-related morphology trends of cortical sulci. Hum. Brain Mapp. 26 (2005), 210–220.
52. [52] Mosconi, L., Tsui, W.H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E.M., Holthoff, V., Kalbe, E., Sorbi, S., Diehl-Schmid, J., Perneczky, R., Clerici, F., Caselli, R., Beuthien-Baumann, B., Kurz, A., Minoshima, S., de Leon, M.J., Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 49 (2008), 390–398.
53. [53] Mosconi, L., Tsui, W.H., Pupi, A., De Santi, S., Drzezga, A., Minoshima, S., de Leon, M.J., 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J. Nucl. Med. 48 (2007), 1129–1134.
54. [54] Alexander, G.E., Chen, K., Pietrini, P., Rapoport, S.I., Reiman, E.M., Longitudinal PET Evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159 (2002), 738–745.
55. [55] Mooradian, A.D., Morin, A.M., Cipp, L.J., Haspel, H.C., Glucose transport is reduced in the blood-brain barrier of aged rats. Brain Res. 551 (1991), 145–149.
56. [56] Hooijmans, C.R., Graven, C., Dederen, P.J., Tanila, H., van Groen, T., Kiliaan, A.J., Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res. 1181 (2007), 93–103.
57. [57] Ding, F., Yao, J., Rettberg, J.R., Chen, S., Brinton, R.D., Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. PLoS One, 8, 2013, e79977.
58. [58] Simpson, I.A., Chundu, K.R., Davies-Hill, T., Honer, W.G., Davies, P., Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35 (1994), 546–551.
59. [59] Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I., Gong, C.X., Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 582 (2008), 359–364.
60. [60] Harr, S.D., Simonian, N.A., Hyman, B.T., Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J. Neuropathol. Exp. Neurol. 54 (1995), 38–41.
61. [61] Kalaria, R.N., Harik, S.I., Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J. Neurochem. 53 (1989), 1083–1088.
62. [62] Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., Kivipelto, M., Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9 (2010), 702–716.
63. [63] Magistretti, P., Allaman, I., Brain energy metabolism. Pfaff, D., (eds.) Neuroscience in the 21st Century, 2013, Springer, New York, 1591–1620.
64. [64] McCommis, K.S., Finck, B.N., Mitochondrial pyruvate transport: a historial perspective and future research directions. Biochem. J. 466 (2015), 443–454.
65. [65] Bender, T., Martinou, J.-C., The mitochondrial pyruvate carrier in health and disease: To carry or not to carry?. Biochim. Biophys. Acta., 2016 pii: S0167-4889(16)30007-6.
66. [66] Sheu, K.F., Kim, Y.T., Blass, J.P., Weksler, M.E., An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann. Neurol. 17 (1985), 444–449.
67. [67] Nave, K.-A., Werner, H.B., Myelination of the nervous systems: mechanisms and functions. Annu. Rev. Cell Dev. Biol. 30 (2014), 503–533.
68. [68] Birsoy, K., Wang, T., Chen, W.W., Frinkman, E., Abu-remaileh, M., Sabatini, D.M., An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162 (2015), 540–551.
69. [69] Sullivan, L.B., Gui, D.Y., Hosios, A.M., Bush, L.N., Frreinkman, E., Vander Heiden, M.G., Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162 (2015), 552–563.
70. [70] Bak, L.K., Schousboe, A., Waagepetersen, H.S., The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 98 (2006), 641–653.
71. [71] Boumezbeur, F., Mason, G.F., de Graaf, R.A., Behar, K.L., Cline, G.W., Shulman, G.I., Rothman, D.L., Petersen, K.F., Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 30 (2010), 211–221.
72. [72] Rothman, D.L., Behar, K.L., Hyder, F., Shulman, R.G., In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu. Rev. Physiol. 65 (2003), 401–427.
73. [73] Miccheli, A., Puccetti, C., Capuani, G., Di Cocco, M.E., Giardino, L., Calzà, L., Battaglia, A., Battistin, L., Conti, F., [1-13C]Glucose entry in neuronal and astrocytic intermediary metabolism of aged rats: a study of the effects of nicergoline treatment by 13C NMR spectroscopy. Brain Res. 966 (2003), 116–125.
74. [74] Nomura, Y., Yamanaka, Y., Kitamura, Y., Arima, T., Ohnuki, T., Oomura, Y., Sasaki, K., Nagashima, K., Ihara, Y., Senescence-accelerated mouse. Neurochemical studies on aging. Ann. NY Acad. Sci. 786 (1996), 410–418.
75. [75] Kondziella, D., Hammer, J., Sletvold, O., Sonnewald, U., The pentylenetetrazole-kindling model of epilepsy in SAMP8 mice: glial–neuronal metabolic interactions. Neurochem. Int. 43 (2003), 629–637.
76. [76] Hyder, F., Patel, A.B., Gjedde, A., Rothman, D.L., Behar, K.L., Shulman, R.G., Neuronal–glial glucose oxidation and glutamatergic–GABAergic function. J. Cereb. Blood Flow Metab. 26 (2006), 865–877.
77. [77] Dedeoglu, A., Choi, J.-K., Cormier, K., Kowall, N.W., Jenkins, B.G., Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 1012 (2004), 60–65.
78. [78] Tiwari, V., Patel, A.B., Impaired glutamatergic and GABAergic function at early age in AβPPswe-PS1dE9 mice: implications for Alzheimer's disease. J. Alzheimers Dis. 28 (2012), 765–769.
79. 13C NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease. J. Neural Transm. 122 (2015), 541–550.
80. 13C NMR study. J. Cereb. Blood Flow Metab. 34 (2014), 288–296.
81. 13C magnetic resonance spectroscopy study. MAGMA 16 (2003), 29–42.
82. [82] Sancheti, H., Patil, I., Kanamori, K., Diaz Brinton, R., Zhang, W., Lin, A.L., Cadenas, E., Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a (13)C-NMR study. J. Cereb. Blood Flow Metab. 34 (2014), 1749–1760.
83. [83] Nilsen, L.H., Rae, C., Ittner, L.M., Götz, J., Sonnewald, U., Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J. Cereb. Blood Flow Metab. 33 (2013), 684–691.
84. [84] Drew, B., Leeuwenburgh, C., Ageing and subcellular distribution of mitochondria: role of mitochondrial DNA deletions and energy production. Acta Physiol. Scand. 182 (2004), 333–341.
85. [85] Navarro, A., Boveris, A., Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants. Adv. Drug Deliv. Rev. 60 (2008), 1534–1544.
86. [86] Bowling, A.C., Mutisya, E.M., Walker, L.C., Price, D.L., Cork, L.C., Beal, M.F., Age-dependent impairment of mitochondrial function in primate brain. J Neurochem. 60 (1993), 1964–1967.
87. [87] Petrosillo, G., Matera, M., Casanova, G., Ruggiero, F.M., Paradies, G., Mitochondrial dysfunction in rat brain with aging: involvement of complex I, reactive oxygen species and cardiolipin. Neurochem. Int. 53 (2008), 126–131.
88. [88] Hauptmann, S., Scherping, I., Drose, S., Brandt, U., Schulz, K.L., Jendrach, M., Leuner, K., Eckert, A., Muller, W.E., Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging 30 (2009), 1574–1586.
89. [89] Yao, J., Irwin, R.W., Zhao, L., Nilsen, J., Hamilton, R.T., Brinton, R.D., Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 106 (2009), 14670–14675.
90. [90] Fukuyama, R., Hatanpää, K., Rapoport, S.I., Chandrasekaran, K., Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer's disease patients. Brain Res. 713 (1996), 290–293.
91. [91] Kim, S.H., Vlkolinsky, R., Cairns, N., Lubec, G., Decreased levels of complex III core protein 1 and complex V β chain in brains from patients with Alzheimer's disease and down syndrome. Cell Mol. Life Sci. 57 (2000), 1810–1816.
92. [92] Parker, W.D.J., Parks, J., Filley, C.M., Kleinschmidt-DeMasters, B.K., Electron transport chain defects in Alzheimer's disease brain. Neurology, 44, 1994, 1090.
93. [93] Kish, S.J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L.J., Wilson, J.M., DiStefano, L.M., Nobrega, J.N., Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59 (1992), 776–779.
94. [94] Dragicevic, N., Mamcarz, M., Zhu, Y., Buzzeo, R., Tan, J., Arendash, G.W., Bradshaw, P.C., Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J. Alzheimers Dis. 20:Suppl. 2 (2010), S535–S550.
95. [95] Bobba, A., Amadoro, G., Valenti, D., Corsetti, V., Lassandro, R., Atlante, A., Mitochondrial respiratory chain complexes I and IV are impaired by beta-amyloid via direct interaction and through complex I-dependent ROS production, respectively. Mitochondrion 13 (2013), 298–311.
96. [96] Markesbery, W., Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997), 134–147.
97. [97] Lin, M., Beal, M., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006), 787–795.
98. [98] Boveris, A., Cadenas, E., Mitochondrial production of superoxide anions and its relationship to the antimycin-insensitive respiration. FEBS Lett. 54 (1975), 311–314.
99. [99] Boveris, A., Cadenas, E., Stoppani, A.O.M., Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem. J. 156 (1976), 435–444.
100. [100] Cadenas, E., Boveris, A., Ragan, C.I., Stoppani, A.O., Production of superoxide radicals and hydrogen peroxide by NADH- ubiquinone reductase and ubiquinol-cytochrome c reductase from beef- heart mitochondria. Arch. Biochem. Biophys. 180 (1977), 248–257.
101. [101] Turrens, J.F., Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003), 335–344.
102. 2, a necessary evil for cell signaling. Science 312 (2006), 1882–1883.
103. [103] Storozhevykh, T.P., Senilova, Y.E., Persiyantseva, N.A., Pinelis, V.G., Pomytkin, I.A., Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. BMC Neurosci., 8, 2007, 84.
104. [104] Persiyantseva, N.A., Storozhevykh, T.P., Senilova, Y.E., Gorbacheva, L.R., Pinelis, V.G., Pomytkin, I.A., Mitochondrial H2O2 as an enable signal for triggering autophosphorylation of insulin receptor in neurons. J. Mol. Signal., 8, 2013, 11.
105. [105] Loh, K., Deng, H., Fukushima, A., Cai, X., Boivin, B., Galic, S., Bruce, C., Shields, B.J., Skiba, B., Ooms, L.M., Stepto, N., Wu, B., Mitchell, C.A., Tonks, N.K., Watt, M.J., Febbraio, M.A., Crack, P.J., Andrikopoulos, S., Tiganis, T., Reactive oxygen species enhance insulin sensitivity. Cell Metab. 10 (2009), 260–272.
106. [106] Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A.L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C.C., Ramachandran, C., Gresser, M.J., Tremblay, M.L., Kennedy, B.P., Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283 (1999), 1544–1548.
107. [107] Antico Arciuch, V.G., Galli, S., Franco, M.C., Lam, P.Y., Cadenas, E., Carreras, M.C., Poderoso, J.J., Akt1 intramitochondrial cycling is a crucial step in the redox modulation of cell cycle progression. PLoS One, 4, 2009, e7523.
108. [108] Iwakami, S., Misu, H., Takeda, T., Sugimori, M., Matsugo, S., Kaneko, S., Takamura, T., Concentration-dependent dual effects of hydrogen peroxide on insulin signal transduction in H4IIEC hepatocytes. PLoS One, 6, 2011, e27401.
109. [109] Aguirre, V., Uchida, T., Yenush, L., Davis, R., White, M.F., The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275 (2000), 9047–9054.
110. [110] Zhou, Q., Lam, P.Y., Han, D., Cadenas, E., c-Jun N-terminal kinase regulates mitochondrial bioenergetics by modulating pyruvate dehydrogenase activity in primary cortical neurons. J. Neurochem. 104 (2008), 325–335.
111. [111] Nemoto, S., Takeda, K., Yu, Z.X., Ferrans, V.J., Finkel, T., Role for mitochondrial oxidants as regulators of cellular metabolism. Mol. Cell Biol. 20 (2000), 7311–7318.
112. [112] Yin, F., Sancheti, H., Cadenas, E., Silencing of nicotinamide nucleotide transhydrogenase impairs cellular redox homeostasis and energy metabolism in PC12 cells. Biochim. Biophys. Acta 1817 (2012), 401–409.
113. [113] Pinzar, E., Wang, T., Garrido, M.R., Xu, W., Levy, P., Bottari, S.P., Angiotensin II induces tyrosine nitration and activation of ERK1/2 in vascular smooth muscle cells. FEBS Lett. 579 (2005), 5100–5104.
114. [114] Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., Ichijo, H., Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998), 2596–2606.
115. 2 sensitivity of the major constitutive MAPK phosphatase from rat brain. Biochem. Biophys. Res. Commun. 315 (2004), 568–574.
116. [116] Adler, V., Funchs, S.Y., Benezra, M., Rosario, L., Tew, K.D., Pincus, M.R., Sardana, M., Henderson, C.J., Wolf, C.R., Davis, R.J., Ronai, Z., Regulation of JNK signaling by GSTp. EMBO J. 18 (1999), 1234–1321.
117. [117] Barone, E., Di Domenico, F., Cassano, T., Arena, A., Tramutola, A., Lavecchia, M.A., Coccia, R., Butterfield, D.A., Perluigi, M., Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: a new paradigm. Free Radic. Biol. Med. 91 (2016), 127–142.
118. [118] Tramutola, A., Triplett, J.C., Di Domenico, F., Niedowicz, D.M., Murphy, M.P., Coccia, R., Perluigi, M., Butterfield, D.A., Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J. Neurochem. 133 (2015), 739–749.
119. [119] Rhee, S.G., Woo, H.A., Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger HO, and protein chaperones. Antioxid. Redox Signal. 15 (2011), 781–794.
120. [120] Dabkowski, E.R., Williamson, C.L., Hollander, J.M., Mitochondria-specific transgenic overexpression of phospholipid hydroperoxide glutathione peroxidase (GPx4) attenuates ischemia/reperfusion-associated cardiac dysfunction. Free Radic. Biol. Med. 45 (2008), 855–865.
121. [121] Yoo, M.H., Gu, X., Xu, X.M., Kim, J.Y., Carlson, B.A., Patterson, A.D., Cai, H., Gladyshev, V.N., Hatfield, D.L., Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer's disease. Antioxid. Redox Signal. 12 (2010), 819–827.
122. [122] Shan, X., Jones, D.P., Hashmi, M., Anders, M.W., Selective depletion of mitochondrial glutathione concentrations by (R,S)-3-hydroxy-4-pentenoate potentiates oxidative cell death. Chem. Res. Toxicol. 6 (1993), 75–81.
123. [123] Muyderman, H., Nilsson, M., Sims, N.R., Highly selective and prolonged depletion of mitochondrial glutathione in astrocytes markedly increases sensitivity to peroxynitrite. J. Neurosci. 24 (2004), 8019–8028.
124. [124] Wüllner, U., Seyfried, J., Groscurth, P., Beinroth, S., Winter, S., Gleichmann, M., Heneka, M., Löschmann, P.A., Schulz, J.B., Weller, M., Klockgether, T., Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Res. 826 (1999), 53–62.
125. [125] Muyderman, H., Wadey, A.L., Nilsson, M., Sims, N.R., Mitochondrial glutathione protects against cell death induced by oxidative and nitrative stress in astrocytes. J. Neurochem. 102 (2007), 1369–1382.
126. [126] Jia, Z., Zhu, H., Misra, H.P., Li, Y., Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide. Brain Res. 1197 (2008), 159–169.
127. [127] Giustarini, D., Dalle-Donne, I., Milzani, A., Rossi, R., Low molecular mass thiols, disulfides and protein mixed disulfides in rat tissues: influence of sample manipulation, oxidative stress and ageing. Mech. Ageing Dev. 132 (2011), 141–148.
128. [128] Rebrin, I., Kamzalov, S., Sohal, R.S., Effects of age and caloric restriction on glutathione redox state in mice. Free Radic. Biol. Med. 35 (2003), 626–635.
129. [129] Vina, J., Sastre, J., Anton, V., Bruseghini, L., Esteras, A., Asensi, M., Effect of aging on glutathione metabolism. Protection by antioxidants. EXS 62 (1992), 136–144.
130. [130] de la Asuncion, J., Millan, A., Pla, R., Bruseghini, L., Esteras, A., Pallardo, F., Sastre, J., Vina, J., Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA. FASEB J. 10 (1996), 333–338.
131. [131] Emir, U.E., Raatz, S., McPherson, S., Hodges, J.S., Torkelson, C., Tawfik, P., White, T., Terpstra, M., Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brain. NMR Biomed. 24 (2011), 888–894.
132. [132] Cruz-Aguado, R., Almaguer-Melian, W., Diaz, C.M., Lorigados, L., Bergado, J., Behavioral and biochemical effects of glutathione depletion in the rat brain. Brain Res. Bull. 55 (2001), 327–333.
133. [133] Dean, O., Bush, A.I., Berk, M., Copolov, D.L., van den Buuse, M., Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behav. Brain Res. 198 (2009), 258–262.
134. [134] Zhang, H., Go, Y.M., Jones, D.P., Mitochondrial thioredoxin-2/peroxiredoxin-3 system functions in parallel with mitochondrial GSH system in protection against oxidative stress. Arch. Biochem. Biophys. 465 (2007), 119–126.
135. [135] Peng, Y., Yang, P.H., Guo, Y., Ng, S.S., Liu, J., Fung, P.C., Tay, D., Ge, J., He, M.L., Kung, H.F., Lin, M.C., Catalase and peroxiredoxin 5 protect Xenopus embryos against alcohol-induced ocular anomalies. Invest. Ophth. Vis. Sci. 45 (2004), 23–29.
136. [136] Cox, A.G., Peskin, A.V., Paton, L.N., Winterbourn, C.C., Hampton, M.B., Redox potential and peroxide reactivity of human peroxiredoxin 3. Biochemistry 48 (2009), 6495–6501.
137. 2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J. Biol. Chem. 285 (2010), 27850–27858.
138. [138] Cox, A.G., Pearson, A.G., Pullar, J.M., Jonsson, T.J., Lowther, W.T., Winterbourn, C.C., Hampton, M.B., Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. Biochem. J. 421 (2009), 51–58.
139. [139] Rhee, S.G., Jeong, W., Chang, T.S., Woo, H.A., Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int. Suppl., 2007, S3–S8.
140. [140] Noh, Y.H., Baek, J.Y., Jeong, W., Rhee, S.G., Chang, T.S., Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. J. Biol. Chem. 284 (2009), 8470–8477.
141. [141] Musicco, C., Capelli, V., Pesce, V., Timperio, A.M., Calvani, M., Mosconi, L., Zolla, L., Cantatore, P., Gadaleta, M.N., Accumulation of overoxidized peroxiredoxin III in aged rat liver mitochondria. Biochim. Biophys. Acta 1787 (2009), 890–896.
142. [142] Ngo, J.K., Davies, K.J., Importance of the lon protease in mitochondrial maintenance and the significance of declining lon in aging. Ann. NY Acad. Sci. 1119 (2007), 78–87.
143. [143] Hattori, F., Murayama, N., Noshita, T., Oikawa, S., Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J. Neurochem. 86 (2003), 860–868.
144. [144] Krapfenbauer, K., Engidawork, E., Cairns, N., Fountoulakis, M., Lubec, G., Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967 (2003), 152–160.
145. [145] Kim, S.H., Fountoulakis, M., Cairns, N., Lubec, G., Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and down syndrome. J. Neural Transm. Suppl., 2001, 223–235.
146. [146] Chen, L., Na, R., Ran, Q., Enhanced defense against mitochondrial hydrogen peroxide attenuates age-associated cognition decline. Neurobiol. Aging 35 (2014), 2552–2561.
147. [147] Seo, M.S., Kang, S.W., Kim, K., Baines, I.C., Lee, T.H., Rhee, S.G., Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275 (2000), 20346–20354.
148. [148] Trujillo, M., Clippe, A., Manta, B., Ferrer-Sueta, G., Smeets, A., Declercq, J.P., Knoops, B., Radi, R., Pre-steady state kinetic characterization of human peroxiredoxin 5: taking advantage of Trp84 fluorescence increase upon oxidation. Arch. Biochem. Biophys. 467 (2007), 95–106.
149. +. Neurosci. Lett. 433 (2008), 219–224.
150. [150] Radyuk, S.N., Michalak, K., Klichko, V.I., Benes, J., Rebrin, I., Sohal, R.S., Orr, W.C., Peroxiredoxin 5 confers protection against oxidative stress and apoptosis and also promotes longevity in Drosophila. Biochem. J. 419 (2009), 437–445.
151. [151] Banmeyer, I., Marchand, C., Clippe, A., Knoops, B., Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide. FEBS Lett. 579 (2005), 2327–2333.
152. [152] Jarvis, R.M., Hughes, S.M., Ledgerwood, E.C., Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells. Free Radic. Biol. Med. 53 (2012), 1522–1530.
153. [153] Sobotta, M.C., Liou, W., Stocker, S., Talwar, D., Oehler, M., Ruppert, T., Scharf, A.N., Dick, T.P., Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat. Chem. Biol. 11 (2015), 64–70.
154. [154] Miranda-Vizuete, A., Damdimopoulos, A.E., Spyrou, G., The mitochondrial thioredoxin system. Antioxid. Redox Signal. 2 (2000), 801–810.
155. [155] Spyrou, G., Enmark, E., Miranda-Vizuete, A., Gustafsson, J., Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem. 272 (1997), 2936–2941.
156. [156] Zhang, R., Al-Lamki, R., Bai, L., Streb, J.W., Miano, J.M., Bradley, J., Min, W., Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ. Res. 94 (2004), 1483–1491.
157. [157] Rojanathammanee, L., Rakoczy, S., Brown-Borg, H.M., Growth hormone alters the glutathione S-transferase and mitochondrial thioredoxin systems in long-living Ames dwarf mice. J. Gerontol. A Biol. Sci. Med. Sci. 69 (2014), 1199–1211.
158. [158] Arodin, L., Lamparter, H., Karlsson, H., Nennesmo, I., Bjornstedt, M., Schroder, J., Fernandes, A.P., Alteration of thioredoxin and glutaredoxin in the progression of Alzheimer's disease. J. Alzheimers Dis. 39 (2014), 787–797.
159. [159] Rohrbach, S., Gruenler, S., Teschner, M., Holtz, J., The thioredoxin system in aging muscle: key role of mitochondrial thioredoxin reductase in the protective effects of caloric restriction?. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006), R927–R935.
160. [160] Patenaude, A., Ven Murthy, M.R., Mirault, M.E., Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J. Biol. Chem. 279 (2004), 27302–27314.
161. [161] Rydstrom, J., Mitochondrial NADPH, transhydrogenase, and disease. Biochim. Biophys. Acta 1757 (2006), 721–726.
162. [162] Hoek, J.B., Rydström, J., Physiological roles of nicotinamide nucleotide transhydrogenase. Biochem. J. 254 (1988), 1–10.
163. [163] Agarwal, A.R., Zhao, L., Sancheti, H., Sundar, I.K., Rahman, I., Cadenas, E., Short-term cigarette smoke exposure induces reversible changes in energy metabolism and cellular redox status independent of inflammatory responses in mouse lungs. Am. J. Physiol.-Lung C 303 (2012), L889–898.
164. [164] Lopert, P., Patel, M., Nicotinamide nucleotide transhydrogenase (Nnt) links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin (Trx/Prx) system. J. Biol. Chem. 289 (2014), 15611–15620.
165. [165] Ghosh, D., Levault, K.R., Brewer, G.J., Relative importance of redox buffers GSH and NAD(P)H in age-related neurodegeneration and Alzheimer disease-like mouse neurons. Aging Cell 13 (2014), 631–640.
166. [166] Nickel, A.G., von Hardenberg, A., Hohl, M., Loffler, J.R., Kohlhaas, M., Becker, J., Reil, J.C., Kazakov, A., Bonnekoh, J., Stadelmaier, M., Puhl, S.L., Wagner, M., Bogeski, I., Cortassa, S., Kappl, R., Pasieka, B., Lafontaine, M., Lancaster, C.R., Blacker, T.S., Hall, A.R., Duchen, M.R., Kastner, L., Lipp, P., Zeller, T., Muller, C., Knopp, A., Laufs, U., Bohm, M., Hoth, M., Maack, C., Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab. 22 (2015), 472–484.
167. [167] Han, D., Canali, R., Garcia, J., Aguilera, R., Gallaher, T.K., Cadenas, E., Sites and mechanisms of aconitase inactivation by peroxynitrite: modulation by citrate and glutathione. Biochemistry 44 (2005), 11986–11996.
168. [168] Nulton-Persson, A.C., Starke, D.W., Mieyal, J.J., Szweda, L.I., Reversible inactivation of alpha-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status. Biochemistry 42 (2003), 4235–4242.
169. [169] Reed, T., Perluigi, M., Sultana, R., Pierce, W.M., Klein, J.B., Turner, D.M., Coccia, R., Markesbery, W.R., Butterfield, D.A., Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30 (2008), 107–120.
170. [170] Garcia, J., Han, D., Sancheti, H., Yap, L.P., Kaplowitz, N., Cadenas, E., Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J. Biol. Chem. 285 (2010), 39646–39654.
171. [171] Lam, P.Y., Yin, F., Hamilton, R.T., Boveris, A., Cadenas, E., Elevated neuronal nitric oxide synthase expression during ageing and mitochondrial energy production. Free Radic. Res. 43 (2009), 431–439.
172. [172] Taylor, E.R., Hurrell, F., Shannon, R.J., Lin, T.K., Hirst, J., Murphy, M.P., Reversible glutathionylation of complex I increases mitochondrial superoxide formation. J. Biol. Chem. 278 (2003), 19603–19610.
173. [173] Chen, Y.R., Chen, C.L., Pfeiffer, D.R., Zweier, J.L., Mitochondrial complex II in the post-ischemic heart: oxidative injury and the role of protein S-glutathionylation. J. Biol. Chem. 282 (2007), 32640–32654.
174. [174] Bubber, P., Haroutunian, V., Fisch, G., Blass, J.P., Gibson, G.E., Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 57 (2005), 695–703.
175. [175] Sultana, R., Butterfield, D.A., Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J. Bioenerg. Biomembr. 41 (2009), 441–446.
176. [176] Agarwal, A.R., Yin, F., Cadenas, E., Short-term cigarette smoke exposure leads to metabolic alterations in lung alveolar cells. Am. J. Respir. Cell Mol. 51 (2014), 284–293.
177. [177] Agarwal, A.R., Yin, F., Cadenas, E., Metabolic shift in lung alveolar cell mitochondria following acrolein exposure. Am. J. Physiol. Lung Cell. Mol. Physiol. 305 (2013), L764–773.
178. [178] Carson, M.J., Doose, J.M., Melchior, B., Schmid, C.D., Ploix, C.C., CNS immune privilege: hiding in plain sight. Immunol. Rev. 213 (2006), 48–65.
179. [179] Farina, C., Aloisi, F., Meinl, E., Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28 (2007), 138–145.
180. [180] Zhang, G., Li, J., Purkayastha, S., Tang, Y., Zhang, H., Yin, Y., Li, B., Liu, G., Cai, D., Hypothalamic programming of systemic ageing involving IKK-beta, NF-kappaB and GnRH. Nature 497 (2013), 211–216.
181. [181] Janssen-Heininger, Y.M., Poynter, M.E., Baeuerle, P.A., Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic. Biol. Med. 28 (2000), 1317–1327.
182. [182] Kabe, Y., Ando, K., Hirao, S., Yoshida, M., Handa, H., Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal. 7 (2005), 395–403.
183. [183] Weinberg, S.E., Sena, L.A., Chandel, N.S., Mitochondria in the regulation of innate and adaptive immunity. Immunity 42 (2015), 406–417.
184. [184] Patten, D.A., Germain, M., Kelly, M.A., Slack, R.S., Reactive oxygen species: stuck in the middle of neurodegeneration. J. Alzheimers Dis. 20:Suppl. 2 (2010), S357–S367.
185. [185] Takada, Y., Mukhopadhyay, A., Kundu, G.C., Mahabeleshwar, G.H., Singh, S., Aggarwal, B.B., Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J. Biol. Chem. 278 (2003), 24233–24241.
186. [186] Pahl, H.L., Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999), 6853–6866.
187. [187] Das, K.C., Lewis-Molock, Y., White, C.W., Activation of NF-kappa B and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am. J. Physiol. 269 (1995), L588–602.
188. [188] Bubici, C., Papa, S., Dean, K., Franzoso, G., Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25 (2006), 6731–6748.
189. [189] Song, Y.S., Park, H.J., Kim, S.Y., Lee, S.H., Yoo, H.S., Lee, H.S., Lee, M.K., Oh, K.W., Kang, S.K., Lee, S.E., Hong, J.T., Protective role of Bcl-2 on beta-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-kappaB and p38 MAP kinase activation. Neurosci. Res. 49 (2004), 69–80.
190. [190] Chongthammakun, V., Sanvarinda, Y., Chongthammakun, S., Reactive oxygen species production and MAPK activation are implicated in tetrahydrobiopterin-induced SH-SY5Y cell death. Neurosci. Lett. 449 (2009), 178–182.
191. [191] Chen, L., Liu, L., Yin, J., Luo, Y., Huang, S., Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway. Int. J. Biochem. Cell Biol. 41 (2009), 1284–1295.
192. [192] Patel, J.R., Brewer, G.J., Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. Exp. Neurol. 213 (2008), 93–100.
193. [193] Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481 (2012), 278–286.
194. [194] Walsh, J.G., Muruve, D.A., Power, C., Inflammasomes in the CNS. Nat. Rev. Neurosci. 15 (2014), 84–97.
195. [195] Abais, J.M., Xia, M., Zhang, Y., Boini, K.M., Li, P.L., Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector?. Antioxid. Redox Signal. 22 (2015), 1111–1129.
196. [196] Rathinam, V.A., Vanaja, S.K., Fitzgerald, K.A., Regulation of inflammasome signaling. Nat. Immunol. 13 (2012), 333–342.
197. [197] Minkiewicz, J., de Rivero Vaccari, J.P., Keane, R.W., Human astrocytes express a novel NLRP2 inflammasome. Glia 61 (2013), 1113–1121.
198. [198] Kahlenberg, J.M., Dubyak, G.R., Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am. J. Physiol. Cell Physiol. 286 (2004), C1100–1108.
199. [199] Kanneganti, T.D., Lamkanfi, M., Kim, Y.G., Chen, G., Park, J.H., Franchi, L., Vandenabeele, P., Nunez, G., Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26 (2007), 433–443.
200. [200] Hornung, V., Bauernfeind, F., Halle, A., Samstad, E.O., Kono, H., Rock, K.L., Fitzgerald, K.A., Latz, E., Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9 (2008), 847–856.
201. [201] Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E., Moore, K.J., Golenbock, D.T., The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9 (2008), 857–865.
202. [202] Zhou, R., Tardivel, A., Thorens, B., Choi, I., Tschopp, J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11 (2010), 136–140.
203. [203] Petrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., Tschopp, J., Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14 (2007), 1583–1589.
204. [204] Tschopp, J., Schroder, K., NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat. Rev. Immunol. 10 (2010), 210–215.
205. [205] Spindel, O.N., Berk, B.C., Redox redux: protecting the ischemic myocardium. J. Clin. Invest. 122 (2012), 30–32.
206. [206] Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B.T., Tschopp, J., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008), 674–677.
207. [207] Meissner, F., Molawi, K., Zychlinsky, A., Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat. Immunol. 9 (2008), 866–872.
208. [208] Cruz, C.M., Rinna, A., Forman, H.J., Ventura, A.L., Persechini, P.M., Ojcius, D.M., ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem. 282 (2007), 2871–2879.
209. [209] Zhou, R., Yazdi, A.S., Menu, P., Tschopp, J., A role for mitochondria in NLRP3 inflammasome activation. Nature 469 (2011), 221–225.
210. [210] Infanger, D.W., Sharma, R.V., Davisson, R.L., NADPH oxidases of the brain: distribution, regulation, and function. Antioxid. Redox Signal. 8 (2006), 1583–1596.
211. [211] Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., Hayakawa, T., Nunomura, A., Chiba, S., Perry, G., Smith, M.A., Fujimoto, S., Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273 (2000), 5–9.
212. [212] Bruce-Keller, A.J., White, C.L., Gupta, S., Knight, A.G., Pistell, P.J., Ingram, D.K., Morrison, C.D., Keller, J.N., NOX activity in brain aging: exacerbation by high fat diet. Free Radic. Biol. Med. 49 (2010), 22–30.
213. [213] Zawada, W.M., Banninger, G.P., Thornton, J., Marriott, B., Cantu, D., Rachubinski, A.L., Das, M., Griffin, W.S., Jones, S.M., Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J. Neuroinflamm., 8, 2011, 129.
214. [214] Han, D., Antunes, F., Canali, R., Rettori, D., Cadenas, E., Voltage-dependent anion channels control the release of superoxide anion from mitochondria to cytosol. J. Biol. Chem. 278 (2003), 5557–5563.
215. [215] Sultana, R., Poon, H.F., Cai, J., Pierce, W.M., Merchant, M., Klein, J.B., Markesbery, W.R., Butterfield, D.A., Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22 (2006), 76–87.
216. [216] Hewinson, J., Moore, S.F., Glover, C., Watts, A.G., MacKenzie, A.B., A key role for redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human monocytes. J. Immunol. 180 (2008), 8410–8420.
217. [217] Abais, J.M., Xia, M., Li, G., Gehr, T.W., Boini, K.M., Li, P.L., Contribution of endogenously produced reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in hyperhomocysteinemia. Free Radic. Biol. Med. 67 (2014), 211–220.
218. [218] Haneklaus, M., O'Neill, L.A., NLRP3 at the interface of metabolism and inflammation. Immunol. Rev. 265 (2015), 53–62.
219. [219] Vandanmagsar, B., Youm, Y.H., Ravussin, A., Galgani, J.E., Stadler, K., Mynatt, R.L., Ravussin, E., Stephens, J.M., Dixit, V.D., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
220. [220] Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M.T., Brickey, W.J., Ting, J.P., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12 (2011), 408–415.
221. [221] Stienstra, R., Joosten, L.A., Koenen, T., van Tits, B., van Diepen, J.A., van den Berg, S.A., Rensen, P.C., Voshol, P.J., Fantuzzi, G., Hijmans, A., Kersten, S., Muller, M., van den Berg, W.B., van Rooijen, N., Wabitsch, M., Kullberg, B.J., van der Meer, J.W., Kanneganti, T., Tack, C.J., Netea, M.G., The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12 (2010), 593–605.
222. [222] Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 (2011), 98–107.
223. [223] Ehses, J.A., Lacraz, G., Giroix, M.H., Schmidlin, F., Coulaud, J., Kassis, N., Irminger, J.C., Kergoat, M., Portha, B., Homo-Delarche, F., Donath, M.Y., IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. USA 106 (2009), 13998–14003.
224. [224] Jager, J., Gremeaux, T., Cormont, M., Le Marchand-Brustel, Y., Tanti, J.F., Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148 (2007), 241–251.
225. [225] Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F., Spiegelman, B.M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996), 665–668.
226. [226] Wilkins, H.M., Carl, S.M., Weber, S.G., Ramanujan, S.A., Festoff, B.W., Linseman, D.A., Swerdlow, R.H., Mitochondrial lysates induce inflammation and Alzheimer's disease-relevant changes in microglial and neuronal cells. J. Alzheimers Dis. 45 (2015), 305–318.
227. [227] Shimada, K., Crother, T.R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V.K., Wolf, A.J., Vergnes, L., Ojcius, D.M., Rentsendorj, A., Vargas, M., Guerrero, C., Wang, Y., Fitzgerald, K.A., Underhill, D.M., Town, T., Arditi, M., Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36 (2012), 401–414.
228. [228] Inoue, K., Microglial activation by purines and pyrimidines. Glia 40 (2002), 156–163.
229. [229] Davalos, D., Grutzendler, J., Yang, G., Kim, J.V., Zuo, Y., Jung, S., Littman, D.R., Dustin, M.L., Gan, W.B., ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8 (2005), 752–758.
230. [230] Norden, D.M., Godbout, J.P., Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol. Appl. Neurobiol. 39 (2013), 19–34.
231. [231] Czirr, E., Wyss-Coray, T., The immunology of neurodegeneration. J. Clin. Invest. 122 (2012), 1156–1163.
232. [232] Youm, Y.H., Grant, R.W., McCabe, L.R., Albarado, D.C., Nguyen, K.Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., Munzberg, H., Rosen, C.J., Ingram, D.K., Salbaum, J.M., Dixit, V.D., Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 18 (2013), 519–532.
233. [233] Campuzano, O., Castillo-Ruiz, M.M., Acarin, L., Castellano, B., Gonzalez, B., Increased levels of proinflammatory cytokines in the aged rat brain attenuate injury-induced cytokine response after excitotoxic damage. J. Neurosci. Res. 87 (2009), 2484–2497.
234. [234] Kitazawa, M., Yamasaki, T.R., LaFerla, F.M., Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann. NY Acad. Sci. 1035 (2004), 85–103.
235. [235] Richard, K.L., Filali, M., Prefontaine, P., Rivest, S., Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 28 (2008), 5784–5793.
236. [236] Reed-Geaghan, E.G., Savage, J.C., Hise, A.G., Landreth, G.E., CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci. 29 (2009), 11982–11992.
237. [237] Neeper, M., Schmidt, A.M., Brett, J., Yan, S.D., Wang, F., Pan, Y.C., Elliston, K., Stern, D., Shaw, A., Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267 (1992), 14998–15004.
238. [238] Schroder, K., Tschopp, J., The inflammasomes. Cell 140 (2010), 821–832.
239. [239] Maccioni, R.B., Rojo, L.E., Fernandez, J.A., Kuljis, R.O., The role of neuroimmunomodulation in Alzheimer's disease. Ann. NY Acad. Sci. 1153 (2009), 240–246.
240. [240] Ballatore, C., Lee, V.M., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8 (2007), 663–672.
241. [241] Imbimbo, B.P., Solfrizzi, V., Panza, F., Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. Front. Aging Neurosci., 2, 2010.
242. [242] Vlad, S.C., Miller, D.R., Kowall, N.W., Felson, D.T., Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70 (2008), 1672–1677.
243. [243] Breitner, J.C., Baker, L.D., Montine, T.J., Meinert, C.L., Lyketsos, C.G., Ashe, K.H., Brandt, J., Craft, S., Evans, D.E., Green, R.C., Ismail, M.S., Martin, B.K., Mullan, M.J., Sabbagh, M., Tariot, P.N., Group, A.R., Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 7 (2011), 402–411.
244. [244] Szekely, C.A., Breitner, J.C., Fitzpatrick, A.L., Rea, T.D., Psaty, B.M., Kuller, L.H., Zandi, P.P., NSAID use and dementia risk in the cardiovascular health study: role of APOE and NSAID type. Neurology 70 (2008), 17–24.
245. [245] Lai, A.Y., McLaurin, J., Clearance of amyloid-beta peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 7 (2012), 165–176.
246. [246] Thored, P., Heldmann, U., Gomes-Leal, W., Gisler, R., Darsalia, V., Taneera, J., Nygren, J.M., Jacobsen, S.E., Ekdahl, C.T., Kokaia, Z., Lindvall, O., Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia 57 (2009), 835–849.